Glenmark Unveils its Strategic Blueprint for Transition Into an Innovation-led Global Pharmaceutical Organization in the Next Decade
– Leverages Company’s Industry-leading Capabilities to Expand Discovery and Development of Glenmark’s Robust Generics and Innovative Portfolio
– Focuses Resources on Growth Catalysts
– Focus on innovative new molecular entities (NME)
– Filing as many as nine new drug application (NDA)/biologic license application (BLAs) in the next 10 years
– Targeting 30 percent of total revenues from specialty and innovation segments over the next decade
Glenmark Pharmaceuticals Ltd. (GPL), a global research-driven, integrated pharmaceutical company headquartered at Mumbai, today announced its ‘Strategic Blueprint to Transition into an Innovation-led Global Pharmaceutical Organization over the next decade’. The Blueprint conveys the company’s greater business alignment, expanding generics to prioritizing research and development efforts in three key therapeutic areas: oncology, respiratory and dermatology. The innovative oncology pipeline, with candidates targeting multiple tumors, is the top priority with the greater promise to deliver novel, first-in-class molecules and help Glenmark evolve into a fully commercialized, innovation-led pharmaceutical company.
“Since 2000, it has been the primary objective of Glenmark to facilitate the company’s evolution from a generics organization to a fully integrated, globally commercialized pharmaceutical company with innovative products,” stated Glenn Saldanha, Chairman & Managing Director. “Over the last 16 years, we have created significant shareholder value and this has been possible because of our continuous investments in R&D. As we prepare for the next wave of growth, we have built strong capabilities that uniquely position us to differentiate our product offerings primarily in our core therapy areas and will invest across the value chain from generics to new molecular entities in our effort to build a truly global pharmaceutical organization,” added Glenn Saldanha.
Glenmark is an early leader at the point of convergence of generic and innovative pharmaceutical R&D, with end-to-end capabilities in R&D to full-scale manufacturing, both in small molecules and novel biologics. The company enjoys an enviable market position of self-reliance, strong IP leadership and a global footprint for rapid market penetration. These intellectual assets are already producing results for the company with a specialty and New Molecular Entity (NME) pipeline consisting of nine assets in the three core areas, four of which are in clinical or late pre-clinical development. The company expects to launch its specialty business in the U.S. with its first FDA NDA approval in respiratory within 3-5 years.
The strategic blueprint also outlines aggressive plans to increase Glenmark’s presence worldwide by strengthening focus on complex generics including injectables, expanding its manufacturing footprint (growing from two formulation facilities to 17). Currently, the company has more than 110 Abbreviated New Drug Application (ANDAs) approved and an additional 135 products in regulatory review or in development in the US. Based on the power of the pipeline, Glenmark expects to file 20-25 ANDAs and launch 20 generic products annually in the US. Its business in emerging markets is also well positioned for continuous and sustained growth over a long period in time.
“Building from our enviably strong foundation has given us operational and financial flexibility that allows us to execute on our ambitious plans; we expect the next wave of our growth to be as impressive as our first,” added Saldanha.